Application of Smart Electric Vehicles in Analyzing Gait Abnormalities in Patients With Neurodegenerative Diseases
Innovative Application of Advanced Intelligent Electric Vehicles in Detecting and Analyzing Gait Abnormalities in Patients With Neurodegenerative Diseases, and Adding Value to the Creation of Improved Walking and Balance
1 other identifier
interventional
120
1 country
1
Brief Summary
To explore the possibility of smart electric vehicles providing comprehensive gait assistance and improvement for patients with neurodegenerative diseases
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable parkinson-disease
Started Aug 2025
Shorter than P25 for not_applicable parkinson-disease
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 20, 2025
CompletedStudy Start
First participant enrolled
August 20, 2025
CompletedFirst Posted
Study publicly available on registry
August 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2025
CompletedDecember 3, 2025
December 1, 2025
2 months
August 20, 2025
December 2, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
6-meter Timed-up-and-Go method
45 minutes of gait training
Study Arms (1)
Treatment arm
EXPERIMENTALGait abnormalities in patients with neurodegenerative diseases.
Interventions
The specific applications of artificial intelligence in intelligent electric vehicles mainly include gait monitoring and analysis, real-time feedback and guidance, autonomous adaptive assistance, safety prevention and warnings, data collection and long-term tracking, as well as adding interactive and entertainment elements.
Eligibility Criteria
You may qualify if:
- Patients with neurodegenerative diseases(such as Parkinson's disease or dementia).
- Age: 60-85 years.
- Capable of walking to some extent, but may have mild to moderate gait disturbances.
- Able to understand the trial procedures and give informed consent.
You may not qualify if:
- Unable to walk or requiring comprehensive physical support.
- Conditions such as heart disease, uncontrolled high blood pressure, or a history of major surgery.
- Severe cognitive impairment preventing understanding of the trial procedures or giving informed consent.
- Visual or auditory impairments severe enough to prevent following trial instructions.
- Participation in other clinical trials within a certain period in the past, which could affect the assessment of results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Shuang Ho Hospital
New Taipei City, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lung Chan, MD, PhD
Taipei Medical University Shuang Ho Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor, Professor, Principal Investigator
Study Record Dates
First Submitted
August 20, 2025
First Posted
August 27, 2025
Study Start
August 20, 2025
Primary Completion
October 15, 2025
Study Completion
October 30, 2025
Last Updated
December 3, 2025
Record last verified: 2025-12